Compare Adaptive Biotechnologies Corp (ADPT) vs Prologis Inc (PLD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Prologis Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Prologis Inc trades at $140.68 (market cap $133.89B). The key difference: Prologis Inc is far larger — about 40.2× Adaptive Biotechnologies Corp's market cap, and Prologis Inc pays a 2.98% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | PLD | |
|---|---|---|
Market Cap | $3.33B | $133.89B |
Sector | Health | Real Estate |
52-Week High | $22.37 | $148.74 |
52-Week Low | $10.24 | $104.08 |
Enterprise Value | $3.19B | $167.77B |
Dividend Yield | — | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Prologis (PLD) trades at $143.61, up 2.98% in the last session, with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with a 41.54% net income margin and a $1.07 dividend payment scheduled for June 30, 2026. Recent news highlights a rejected $16.6 billion takeover bid for Segro, indicating aggressive growth ambitions. Cash flow trends remain volatile, with 2025 net cash flow negative at -$172.94 million, though operating cash flow stays robust at $5.01 billion.
Outlook is positive with a consensus price target of $155.20, offering 8% upside. Risks include rising debt-to-asset ratio (37.2% in 2025) and macroeconomic sensitivity. The bullish analyst consensus (57% buy ratings) supports growth from data center expansion and rent spreads, but investors should monitor leverage and acquisition integration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
